This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data
by Zacks Equity Research
Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Loss Narrows in Q1, Focus on Batoclimab
by Zacks Equity Research
Immunovant's (IMVT) earnings beat estimates in the fiscal first quarter ended on Jun 30, 2022. The company is evaluating batoclimab in a pivotal study for treating myasthenia gravis.
All You Need to Know About Geron (GERN) Rating Upgrade to Strong Buy
by Zacks Equity Research
Geron (GERN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies
by Zacks Equity Research
Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.
Endo (ENDP) Phase II Study for Frozen Shoulder Disappoints
by Zacks Equity Research
Endo (ENDP) mid-stage study of collagenase clostridium histolyticum (or CCH) for treating frozen shoulder disappoints.
Novartis (NVS) Announces Positive Data on Oncology Drug
by Zacks Equity Research
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
by Zacks Equity Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
by Zacks Equity Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
by Zacks Equity Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
by Zacks Equity Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion
by Zacks Equity Research
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
by Zacks Equity Research
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
Bausch (BHC) Suspends IPO Plans for Solta Medical
by Zacks Equity Research
Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.
Roche (RHHBY) Alzheimer's Disease Drug Data Disappoints
by Zacks Equity Research
Roche's (RHHBY) study evaluating crenezumab in autosomal dominant Alzheimer's disease did not slow or prevent cognitive decline in people with a specific genetic mutation that causes its early onset.
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
by Zacks Equity Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.
Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug
by Zacks Equity Research
Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.
Zacks Industry Outlook Highlights Alkermes, Geron, Immunocore and BELLUS Health
by Zacks Equity Research
Alkermes, Geron, Immunocore and BELLUS Health have been highlighted in this Industry Outlook article.
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
Has Geron (GERN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.